Skip to main content
Cytogen, Inc. logo

Cytogen, Inc. — Investor Relations & Filings

Ticker · 217330 ISIN · KR7217330000 KO Manufacturing
Open in API
Filings indexed 437 across all filing types
Latest filing 2022-09-14 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 217330

About Cytogen, Inc.

https://www.cytogenlab.com/

Cytogen, Inc. is a biotechnology company specializing in liquid biopsy platforms for precision oncology. The company has developed proprietary technology for the rapid isolation and analysis of viable Circulating Tumor Cells (CTCs) from whole blood. Its core offering, the SmartBiopsy Platform, utilizes a high-density microporous chip with microfluidics and nanotechnology to capture CTCs efficiently. This non-invasive diagnostic approach is designed to support early cancer detection, treatment monitoring, and the advancement of personalized medicine for cancer patients.

Recent filings

Filing Released Lang Actions
주권매매거래정지(무상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a short regulatory notice regarding a temporary suspension of stock trading (주권매매거래정지) for Cytogen due to a bonus issue (무상증자). It cites KOSDAQ market disclosure regulations. Since it is a specific regulatory announcement regarding trading status that does not fit into categories like share issuance or delisting, it falls under the general regulatory filing category.
2022-09-14 Korean
주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from Cytogen, specifically detailing a 'Decision on Bonus Issue' (무상증자결정). This involves the issuance of new shares to existing shareholders without additional payment, which falls under capital changes. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the appropriate category for announcements regarding new share issues or capital structure changes.
2022-09-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements of major shareholders (Jeon Byung-hee and others) in Cytogen. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-08-31 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a 'Stock Collateral Agreement involving a change in the largest shareholder' (최대주주 변경을 수반하는 주식 담보제공 계약 체결). This type of filing relates to financing activities and capital structure changes, specifically detailing collateralized shares by the largest shareholder. Since it involves financing/capital structure updates and does not fit into specific categories like M&A or Share Issues, it is classified as a Capital/Financing Update.
2022-08-31 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (주주총회소집공고) for Cytogen Co., Ltd. It details the meeting date, location, agenda items (such as amendments to the articles of incorporation, director compensation limits, and stock option grants), and voting procedures including electronic voting. This document is a standard proxy solicitation material sent to shareholders to inform them of an upcoming meeting and request their participation/votes. Therefore, it falls under the 'Proxy Solicitation & Information Statement' category.
2022-08-24 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company '주식회사 싸이토젠' (Cytogen Co., Ltd.) covering the period from January 1, 2022, to June 30, 2022. It contains detailed financial information, business descriptions, and management disclosures typical of a formal interim/quarterly report filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). It is not an announcement of a report, but the report itself. H1 2022
2022-08-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.